Asfotase Alfa comment watch save
BreastfeedingGeriatric

  • TRADE NAME: Strensiq (Alexion)
  • INDICATIONS: Perinatal/infantile-and juvenile-onset hypophosphatasia
  • CLASS: Enzyme replacement
  • HALF-LIFE: 5 days
  • FDA APPROVAL DATE: 10/23/2015
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    None known
  • PREGNANCY: No available data

Please login to view the rest of this drug profile.

Page last updated 07/31/2023

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top